NASDAQ:TSHA
Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc.'s revenue grew 17.3% in fiscal 2025 to $9.8M while operating margin fell to −1130.6%. Free cash flow was −$93.8M, −960.1% of revenue, and the diluted share count rose 27.8%.Summary generated from Taysha Gene Therapies, Inc.'s SEC filings. Latest annual report filed Mar 19, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$9.8M
Revenue growth+17.3%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−1130.6%
Net margin−1115.3%
ROICn/a
Return on equity−68.5%
Debt / equity0.20
Free cash flow−$93.8M
FCF margin−960.1%
Share count change+27.8%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | 3 | 15 | 8 | 10 |
| Operating income | −173 | −162 | −72 | −91 | −110 |
| Net income | −175 | −166 | −112 | −89 | −109 |
| Free cash flow | −132 | −109 | −77 | −82 | −94 |
Recent filings
- 10-QQuarterly report for the period ended Jun 30, 2026
Aug 11, 2026 - 8-KResults of operations and financial condition
Aug 11, 2026 - 4Insider transaction report
Jul 10, 2026 - 8-KEntry into a material agreement
Jun 25, 2026 - 8-KRegulation FD disclosure
Jun 22, 2026 - 4Insider transaction report
Jun 2, 2026 - 8-KResults of a shareholder vote
Jun 2, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 6, 2026